Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer

Head and Neck

Volumn 37, Issue 5, 2015, Pages 727-734

  Martinez, Victor D ^a   Vucic, Emily A ^a   Thu, Kelsie L ^a   Pikor, Larissa A ^a   Lam, Stephen ^a   Lam, Wan L ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

gene disruption; head and neck squamous cell carcinoma (HNSCC); KEAP1 CUL3 RBX1 E3 ubiquitin ligase complex; NRF2; survival

Indexed keywords

CUL3 PROTEIN; DNA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; RBX1 PROTEIN; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CARRIER PROTEIN; CUL3 PROTEIN, HUMAN; CULLIN; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; RBX1 PROTEIN, HUMAN; SIGNAL PEPTIDE; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; GENE DISRUPTION; GENE EXPRESSION; GENETIC ASSOCIATION; GENOME; GENOMICS; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; CARCINOMA, SQUAMOUS CELL; FACTUAL DATABASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK NEOPLASMS; KAPLAN MEIER METHOD; MALE; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SURVIVAL;

CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CULLIN PROTEINS; DATABASES, FACTUAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; NF-E2-RELATED FACTOR 2; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 84928211509     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23663     Document Type: Article

References (27)

1. Haddad RI, Shin DM,. Recent advances in head and neck cancer. New Engl J Med 2008; 359: 1143-1154.
2. Amornphimoltham P, Sriuranpong V, Patel V, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004; 10 (12 Pt 1): 4029-4037.
3. Leemans CR, Braakhuis BJ, Brakenhoff RH,. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9-22.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
5. Yoo GH, Piechocki MP, Oliver J, et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope 2004; 114: 1871-1879.
6. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society; 2013.
7. Chari R, Thu KL, Wilson IM, et al. Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev 2010; 29: 73-93.
8. The Cancer Genome Atlas. Head and neck squamous cell carcinoma; 2013. Available at: http://cancergenome.nih.gov/cancersselected/headandneck. Accessed July 1, 2013.
9. Ishii T, Itoh K, Takahashi S, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000; 275: 16023-16029.
10. Kensler TW, Wakabayashi N, Biswal S,. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116.
11. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA,. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 2004; 24: 8477-8486.
12. Niture SK, Jaiswal AK,. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem 2012; 287: 9873-9886.
13. Mitsuishi Y, Taguchi K, Kawatani Y, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012; 22: 66-79.
14. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
15. Shelton P, Jaiswal AK,. The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J 2013; 27: 414-423.
16. Stacy DR, Ely K, Massion PP, et al. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 2006; 28: 813-818.
17. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-1160.
18. Shibata T, Ohta T, Tong KI, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 2008; 105: 13568-13573.
19. Thu KL, Pikor LA, Chari R, et al. Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer. J Thorac Oncol 2011; 6: 1521-1529.
20. Broad Institute TCGA Genome Data Analysis Center. Analysis overview for head and neck squamous cell carcinoma (primary solid tumor cohort), April 21, 2013. Available from Broad Institute of MIT and Harvard.
21. Reva B, Antipin Y, Sander C,. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011; 39: e118.
22. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.
23. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-15550.
24. Sporn MB, Liby KT,. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012; 12: 564-571.
25. Konstantinopoulos PA, Spentzos D, Fountzilas E, et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011; 71: 5081-5089.
26. Solis LM, Behrens C, Dong W, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010; 16: 3743-3753.
27. Shibata T, Saito S, Kokubu A, Suzuki T, Tamamoto M, Hirohashi S,. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway. Cancer Res 2010; 70: 9095-9105.